Advances in Hyperkalemia Management: Implications for Patients and Providers

Conventional treatment of hyperkalemia is restricted by adverse events, as well as a dearth of evidence supporting clinical use (specifically with sodium polystyrene sulfonate). For medication-induced hyperkalemia, treatment involves a dose decrease or discontinuation of the offending agent (usually a renin-angiotensin-aldosterone system inhibitor [RAASI]); however, this often prevents patients from receiving appropriate guideline-directed management. Recent research has led to the development of two novel potassium binders with good safety profiles that allow patients to maintain or increase the use of RAASIs for cardio- and reno-protection.

This CME activity, Advances in Hyperkalemia Management: Implications for Patients and Providers, will help participating clinicians identify those patient populations most likely to present with or develop hyperkalemia, and utilize the appropriate conventional and/or novel agents to correct subacute hyperkalemia.
Learning Objectives

Upon completion of this activity, participants should be better able to:

Compare and contrast safety and efficacy data on novel and conventional agents for correcting subacute/chronic hyperkalemia
Identify patient populations likely to present with or develop hyperkalemia
Incorporate novel agents for correcting subacute hyperkalemia into patient care plans